Multi-molecular imaging showing tumour heterogeneity and differing diagnostic performance in a case with metastatic
Fredrik Hedeer1, Jenny Oddstig2, Páll Hallgrimson3
1Department of Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Entrégatan 7, Lund, S-221 85, Sweden. Fredrik.Hedeer@med.lu.se.
None:
A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [18F]-metafluorobenzylguanidine (mFBG), [68Ga]Ga-DOTA-TOC and [18F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [123I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [18F]-mFBG-PET, and revealed insights into tumour heterogeneity.
